BiomX Inc. 8-K

What Happened

• BiomX Inc. (PHGE) filed an 8-K (Item 5.02) reporting that on May 27, 2026 its Board appointed Roy Rousso to serve as Chief Business Officer, effective July 1, 2026. The company and Mr. Rousso entered into a Consulting Agreement (dated May 20, 2026) describing his compensation, equity award opportunity and other terms.

Key Details

• Appointment dates: Board appointment on May 27, 2026; role effective July 1, 2026.
• Cash pay: Agreement sets a monthly fee of $17,000, pro-rated to a 70% engagement level (equal to $11,900 per month), payable monthly in arrears.
• Bonus: Eligible for an annual performance bonus up to 50% of the base fee actually paid for the period, based on Board-established milestones or at the Board’s discretion.
• Equity: Entitled (subject to Board approval and a yet-to-be-established equity plan) to an award of 200,000 common shares vesting in three equal annual installments starting July 1, 2026; special vesting acceleration/credit applies if terminated without cause or upon a change of control.
• Other terms: Termination for cause is immediate; without cause requires 60 days’ notice (or pay in lieu); Mr. Rousso may terminate with 60 days’ notice. Agreement includes indemnification, D&O insurance, confidentiality, 12‑month non‑competition and 12‑month non‑solicitation covenants. No family relationships or related-party transactions requiring disclosure were reported. The Consulting Agreement is filed as Exhibit 10.1.

Why It Matters

• This 8-K signals a leadership hire focused on business development and partnerships. The cash cost to the company is modest (~$11,900/month at 70% engagement), while the 200,000‑share equity award could dilute shareholders if issued and vests.
• Investors should note the effective date (July 1, 2026), the performance bonus and the equity terms (including acceleration on certain terminations), since these affect executive incentives and potential future dilution.